These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 11583937)

  • 1. Target of rapamycin (TOR) inhibition in renal transplantation: Clinical uses in various populations. Introduction.
    Hricik DE
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 2):S1-2. PubMed ID: 11583937
    [No Abstract]   [Full Text] [Related]  

  • 2. Sirolimus and mycophenolate mofetil for calcineurin-free immunosuppression in renal transplant recipients.
    Pescovitz MD; Govani M
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 2):S16-21. PubMed ID: 11583940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclosporine elimination in the presence of TOR inhibitors: effects on renal function, acute rejection, and safety.
    Velosa JA; Larson TS; Gloor JM; Stegall MD
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 2):S3-S10. PubMed ID: 11583938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of TOR inhibitors and other immunosuppressive regimens in African-American renal transplant recipients.
    Hricik DE
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 2):S11-5. PubMed ID: 11583939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapamycin use and rapid withdrawal of calcineurin inhibitors in pediatric renal transplantation.
    Vilalta R; Vila A; Nieto J; Callís L
    Transplant Proc; 2003 Mar; 35(2):703-4. PubMed ID: 12644102
    [No Abstract]   [Full Text] [Related]  

  • 6. Conversion of calcineurin inhibitors with mammalian target of rapamycin inhibitors after kidney transplant.
    Nikoueinejad H; Soleimani A; Mirshafiey A; Amirzargar A; Sarrafnejad A; Kamkar I; Einollahi B
    Exp Clin Transplant; 2013 Feb; 11(1):12-6. PubMed ID: 23387537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients.
    Ettenger RB; Grimm EM
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 2):S22-8. PubMed ID: 11583941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A calcineurin antagonist-free induction immunosuppression strategy for delayed graft function in renal transplantation.
    Hong JC; Kahan BD
    Transplant Proc; 2001; 33(1-2):1271-2. PubMed ID: 11267288
    [No Abstract]   [Full Text] [Related]  

  • 9. Systematic Review on Role of Mammalian Target of Rapamycin Inhibitors as an Alternative to Calcineurin Inhibitors in Renal Transplant: Challenges and Window to Excel.
    Kumar J; Bridson JM; Sharma A; Halawa A
    Exp Clin Transplant; 2017 Jun; 15(3):241-252. PubMed ID: 27915965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sirolimus to replace calcineurin inhibitors? Too early yet.
    Cravedi P; Ruggenenti P; Remuzzi G
    Lancet; 2009 Apr; 373(9671):1235-6. PubMed ID: 19362662
    [No Abstract]   [Full Text] [Related]  

  • 11. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
    Höcker B; Tönshoff B
    Paediatr Drugs; 2011 Feb; 13(1):49-69. PubMed ID: 21162600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conversion to rapamycin in renal allograft recipients with biopsy-proven calcineurin inhibitor-induced nephrotoxicity.
    Diekmann F; Waiser J; Fritsche L; Dragun D; Neumayer HH; Budde K
    Transplant Proc; 2001; 33(7-8):3234-5. PubMed ID: 11750386
    [No Abstract]   [Full Text] [Related]  

  • 13. mTOR Inhibition and Clinical Transplantation: Kidney.
    Flechner SM
    Transplantation; 2018 Feb; 102(2S Suppl 1):S17-S18. PubMed ID: 28230636
    [No Abstract]   [Full Text] [Related]  

  • 14. Rationale for using belatacept in combination with sirolimus.
    Wéclawiak H; Kamar N; Ould-Mohamed A; Cardeau-Desangles I; Rostaing L
    Transplant Proc; 2010 Nov; 42(9 Suppl):S29-31. PubMed ID: 21095447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of sirolimus in kidney transplantation.
    Podbielski J; Schoenberg L
    Prog Transplant; 2001 Mar; 11(1):29-32. PubMed ID: 11357554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of low-dose calcineurin inhibitors on acute rejection and graft survival.
    Altaca G; Berber I; Aydin C; Titiz I
    Transplant Proc; 2002 Sep; 34(6):2079-80. PubMed ID: 12270320
    [No Abstract]   [Full Text] [Related]  

  • 17. SDZ RAD. Rapamycin SDZ.
    Drugs R D; 1999 Jan; 1(1):97-9. PubMed ID: 10566000
    [No Abstract]   [Full Text] [Related]  

  • 18. Mammalian Target of Rapamycin Inhibitor Monotherapy: Efficacy in Renal Transplantation.
    Franco A; Más-Serrano P; Perez Contreras J; Jiménez L; Rodriguez D; Olivares J
    Transplant Proc; 2015 Oct; 47(8):2364-7. PubMed ID: 26518928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of a combination therapy using calcineurin inhibitor and mTOR inhibitor in preventing allograft rejection and post-transplantation renal cancer progression.
    Basu A; Liu T; Banerjee P; Flynn E; Zurakowski D; Datta D; Viklicky O; Gasser M; Waaga-Gasser AM; Yang J; Pal S
    Cancer Lett; 2012 Aug; 321(2):179-86. PubMed ID: 22343319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sirolimus is effective for prevention of acute rejection in primary mismatched renal allograft recipients.
    Ponticelli C
    Transplant Proc; 2001; 33(1-2):1031-2. PubMed ID: 11267177
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.